热门资讯> 正文
Alterity报告了多系统萎缩研究的数据
2025-07-28 22:33
- Alterity Therapeutics (NASDAQ:ATHE) shared positive results on Monday from a mid-stage trial of its main drug candidate, ATH434-202, to treat multiple system atrophy.
- During the trial, ATH434 showed positive effects on overall neurological symptoms in 30% of patients. Brain imaging tests indicated that the drug effectively engaged its target and helped slow down brain shrinkage.
- The company said that ATH434 was well-received by patients, demonstrating a good safety profile.
More on Alterity Therapeutics
- Seeking Alpha’s Quant Rating on Alterity Therapeutics
- Historical earnings data for Alterity Therapeutics
- Financial information for Alterity Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
